A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cirrhosis

Interventions

DRUG: ustekinumab 90 mg
DRUG: ustekinumab 45 mg
DRUG: ustekinumab 180 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC